Solution structure of an ultra-stable single-chain insulin analog connects protein dynamics to a novel mechanism of receptor binding by Glidden, Michael D. et al.
Solution structure of an ultra-stable single-chain insulin
analog connects protein dynamics to a novel mechanism of
receptor binding
Received for publication, July 26, 2017, and in revised form, October 12, 2017 Published, Papers in Press, November 7, 2017, DOI 10.1074/jbc.M117.808667
Michael D. Glidden‡§1, Yanwu Yang‡, Nicholas A. Smith¶, Nelson B. Phillips‡2, Kelley Carr‡,
Nalinda P. Wickramasinghe‡, Faramarz Ismail-Beigi‡§, Michael C. Lawrence**‡‡, Brian J. Smith¶,
andMichael A.Weiss‡§§3
From the Departments of ‡Biochemistry, §Physiology and Biophysics, Medicine, and §§Biomedical Engineering, CaseWestern
Reserve University, Cleveland, Ohio 44106, the ¶La Trobe Institute for Molecular Science, La Trobe University, Melbourne,
Victoria 3086, Australia, **TheWalter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville,
Victoria 3052, Australia, and the ‡‡Department of Medical Biology, University of Melbourne, Parkville, Victoria 3010, Australia
Edited by Jeffrey E. Pessin
Domain-minimized insulin receptors (IRs) have enabled crys-
tallographic analysis of insulin-bound “micro-receptors.” In
such structures, the C-terminal segment of the insulin B chain
inserts between conserved IR domains, unmasking an invariant
receptor-binding surface that spans both insulinA andB chains.
This “open” conformation not only rationalizes the inactivity of
single-chain insulin (SCI) analogs (in which the A and B chains
are directly linked), but also suggests that connecting (C)
domains of sufficient lengthwill bind the IR.Here, we report the
high-resolution solution structure and dynamics of such an
active SCI. The hormone’s closed-to-open transition is fore-
shadowed by segmental flexibility in the native state as probed
by heteronuclear NMR spectroscopy and multiple conformer
simulations of crystallographic protomers as described in the
companion article. We propose a model of the SCI’s IR-bound
state based on molecular-dynamics simulations of a micro-re-
ceptor complex. In this model, a loop defined by the SCI’s B and
C domains encircles the C-terminal segment of the IR -sub-
unit. This binding mode predicts a conformational transition
between an ultra-stable closed state (in the free hormone) and
an active open state (on receptor binding). Optimization of this
switch within an ultra-stable SCI promises to circumvent ins-
ulin’s complex global cold chain. The analog’s biphasic activity,
which serendipitously resembles current premixed formula-
tions of soluble insulin andmicrocrystalline suspension,may be
of particular utility in the developing world.
Insulin is a small globular protein that regulates metabolic
homeostasis in vertebrates. A classicalmodel for studies of pro-
tein structure and long a mainstay of therapy for diabetes mel-
litus (DM),4 insulinwas the first recombinant protein in clinical
use and a pioneering target of protein engineering (1).Whereas
design of first-generation analogs sought to optimize pharma-
cokinetic (PK) properties (i.e. rapid- or long-acting therapeutic
formulations), recent efforts have focused on protein stability
(2–4). Ultra-stable insulin analogs promise to circumvent a
costly “cold chain” underlying its global distribution (2). The
salience of this issue has been sharpened by an emerging pan-
demic of DM in the developing world (5).
Insulin contains two chains:5 an A chain (21 residues) and B
chain (30 residues) (Fig. 1A) (6). Themature hormone nonethe-
less belongs to a metazoan superfamily of single-chain proteins
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(7) and itself derives from a single-chain precursor (proinsulin
(8)). In the accompanying article (9), we described an ultra-
stable single-chain insulin analog (labeled SCI-a; Fig. 1C) with
appropriate biological activity (including duration of signaling)
in a rat model (9). The crystal structure of SCI-a, determined as
a non-canonical zinc-free hexamer, revealed native-like com-
ponent dimers with apparent disorder in the engineered C
domains and adjoining B domain residues. Because of this
structure’s limited resolution (2.8 Å) and incomplete elec-
tron density, we sought a high-resolution solution structure
and its dynamic assessment. This study thus focused on a
monomeric variant of SCI-a, viz. SCI-b, that is amenable to
heteronuclear 3D/4D-NMR spectroscopy (10, 11). SCI-b dif-
fered from its parent at residues B28 and B29, recapitulating
features of rapid-acting insulin analogs (Fig. 1B) (12, 13).
Intravenous (i.v.) bolus injection of SCI-b led, for unknown
reasons, to protracted insulin action (9), similar to that of
ultra-stable two-chain insulin analog cross-linked by an
additional disulfide bridge (3). The monophasic pharmaco-
dynamics (PD) profile of SCI-a by contrast resembled that of
wild-type (WT) insulin (9).
Insulin binds as a monomer to a receptor tyrosine kinase
(TK), the insulin receptor (IR). The product of a single gene, the
IR precursor is processed in the trans-Golgi network to form a
disulfide-linked ()2 homodimer (14). The extracellular 
subunits bind insulin, and the transmembrane  subunits con-
tain the intracellular TK domains (15). Whereas the structure
of the holoreceptor has been visualized only at low resolution
(20 Å (16)), its domain dissection has enabled stepwise crys-
tallographic analysis. (i) Structures of the intracellular TK
domains and theirmode of interaction have been determined at
a resolution of 1.9 Å (17, 18). (ii) The structure of the N-termi-
nal three domains of the  subunit (Leu-rich domain 1, Cys-
rich domain, and Leu-rich domain 2; L1-CR-L2) has been
determined at 2.3 Å (19). (iii) The structure of the dimeric ect-
odomain (()2, containing the entire subunit and the extra-
cellular portion of the subunit,) has been determined at 3.3
Å (20), wherein its conformation resembles an inverted V.
Although co-crystals of an insulin–ectodomain complex have
not been obtained, a variety of evidence indicates that insulin
binds within the crux of the dimer (15, 21, 22).
Construction of domain-minimized models of the IR  sub-
unit has enabled crystallization of “micro-receptor” (IR) com-
plexes (15, 21). Such complexes contain, at a minimum, the
primary insulin-binding elements L1 and CT stabilized by an
Fab antibody fragment. One such co-crystal structure, deter-
mined at 3.5 Å resolution, depicted a ternary complex between
insulin, an L1-CR fragment, and a synthetic CT peptide span-
ning residues 704–719 of IR isoform A (15). In this structure
the C-terminal segment of the insulin B chain pivots from
the hormone’s -helical core to enable its insertion bet-
ween the conserved surfaces of L1 and the CT peptide. This
mode of binding, anticipated based on studies of anomalous
insulin analogs (23, 24) and residue-specific photo-cross-
linking (25), defined the binding surfaces in the IR for ins-
ulin’s conserved triplet of aromatic residues: PheB24, PheB25,
and TyrB26. The side chain of TyrB26, although important for
insulin self-assembly (6), packs at a solvated edge of the IR
(15) and can be substituted by Ala, Ser, or Glu without loss of
affinity (26).
The solution structure of SCI-b presented here contains a
well-ordered -helical domain whose overall structure is simi-
lar to corresponding portions of the crystallographic protomers
of SCI-a. The latter resemble T-state protomers as observed in
T6 crystal structures of WT insulin (9). The B chain -strand
(residues B24–B28) exhibits local order in the absence of a
dimer-related -sheet, but its precise positioning relative to
the A and B domain -helices differs from crystallographic
dimers (9). The C domain is less well-ordered than the glob-
ular domain, but its ensemble of conformations is not ran-
dom; non-polar and electrostatic contacts with residues in
the N-terminal -helix of the A domain are on average main-
tained. Order parameters derived from 13C chemical shifts
and 1H-15N relaxation studies are in accordance with these
trends.
NMR-derived structures of proteins are ordinarily based on
the assumption that all restraints (as derived from nuclear
Overhauser effects (NOEs), J-coupling constants, and patterns
of chemical shifts (27)) are enforced simultaneously (28). This
assumptionmay not be valid in the presence of local or segmen-
talmobility (29). Accordingly, we have extended suchmodeling
through use of time-averaged molecular-dynamics (MD) sim-
ulations in which all or part of the protein satisfies the NMR-
derived restraints only as time-averaged in an MD trajectory
(30, 31). This dynamic view was extended by simulated
annealing (SA) and multiconformer simulation within the
SCI-a crystal lattice to obtain an ensemble of possible states.
A third and more distantly related ensemble was obtained
through MD simulations of SCI-b as docked within a IR
complex (15, 21). Comparison of these ensembles highlights
the role of segmental mobility in the mechanism of receptor
binding.
Together, our results imply a functional transition between
an ultra-stable closed state in the free hormone and an active
open state on receptor binding. A model of an SCI–IR com-
plex is proposed in which the critical IR CT element “threads”
within a loop opened by displacement of the B domain C-ter-
minal segment and bounded by a disorderedC domain. Beyond
these mechanistic implications, the biphasic PD features of
SCI-b in vivo closely matched the dual-action profile of pre-
mixed soluble and microcrystalline insulin formulations (32):
regimens with potential benefits amongminority communities
in theWest (33) and of broad current use inAfrica (34) andAsia
(35). The biphasic action profile of the present SCI together
with its extraordinary resistance to thermal degradation (9)
may enhance access to insulin among underprivileged patients
in the developing world (2, 5).
Results
SCI-a and SCI-b are described in the accompanying article
(9). Designed based on prior studies of two-chain insulin ana-
logs (12, 13), chemically cross-linked analogs (36), and an SCI
prototype (4), these proteins contain sequence elements
intended to co-optimize specific biochemical and biophysical
properties (Fig. 1C). Whereas SCI-a (amenable to protective
self-assembly) was envisaged as a therapeutic candidate, SCI-b
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provides a monomeric model amenable to high-resolution
NMR study. Paired substitutions AspB28 and ProB29 combine
features of two rapid-acting analogs in current clinical use
(insulins lispro and aspart) (Fig. 1B) (12, 13). Dimerization and
in turn higher-order assembly are impaired by (i) the absence of
proline at B28, whose pyrrolidine ring engages GlyB23 across
the dimer interface (37), and (ii) the negative charge of AspB28
itself (1). The tractability of the one-dimensional 1HNMRspec-
trum of SCI-b at high protein concentration (9) motivated its
present uniform 15N/13C-labeling in yeast Pichia pastoris; het-
eronuclear resonances assignments were obtained by standard
methods (10, 27).
Figure 1. Structural overview and insulin analog sequences. A, crystal structure of WT porcine insulin (PDB code 4INS (6)) from two perspectives showing
A (green) and B (blue) chains and disulfide bridges (yellow sticks): A20–B19, A7–B7, and A6–A11 (black boxed labels). Side chains of ThrA8 and TyrA14 are
highlighted as red sticks. The C-terminal B chain segment is labeled. B, protein sequences of WT insulin, insulin aspart, and insulin lispro. C, protein sequences
of novel single chains SCI-a and SCI-b aswell as progenitor SCI-c (4). SCIs contain a six-residue Cdomain; peptide bonds connecting theA andBdomains to the
C domain are shown as red lines. Substitutions relative toWT insulin in B and C are shown in red. Gold lines in sequences indicate disulfide bonds. Black arrows
at bottom of C highlight residues B10, B28, B29, and A14.
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Solution structure resembles crystallographic protomers
The solution structure of SCI-bwas calculated on the basis of
1370 NOE distance restraints (average of 24 per residue; Table
S1) and 75 dihedral angle restraints. An ensemble, based on
simultaneous enforcement of these restraints, contains a
native-like insulin fold (A and B domains; green and blue in Fig.
2, A and B) connected by the 6-residue C domain (red in Fig. 2,
A and B). Statistics are given in Table S1. The SCI-b core is
similar to that of WT insulin (gray in Fig. 2C) and our previous
SCI prototype (gray ensemble in Fig. 2D). In the SCI-b mono-
mer residues, B23–B28 appear less well-ordered and displaced
relative to the corresponding segments at a classical dimer
interface in SCI-a (9), wherein B24–B28 and its dimer-related
partner form an anti-parallel -sheet (6). Following helical
alignment of the SCI-b ensemble to all protomers of SCI-a (Fig.
3A), themean root-mean-square deviations (r.m.s.d.) of respec-
tive residues B24–B26 are 1.2(0.3), 1.3(0.3), and 2.0(0.5)
Å, respectively. SCI-b also differs from crystallographic
protomers of SCI-a in the presumed orientation of the B27-C6
segment, although well-defined electron density in the latter
structure was not observed (9).
The C domain is neither well-ordered nor disordered. Its
ensemble of trajectories spans a crevice between A and B
domains. Segmental imprecision reflected a lower density of
NOE restraints; evidence of underlying dynamic disorder is
presented below. Apparently, stabilizing interactions were
introduced by the arginine guanidinium groups as follows (Fig.
2, E–G). (i) The N-terminal portion of the A1–A8 -helix
extends to include residues C4–C6 (sequence PRR) as demon-
strated by the proximity of ProC4 and ValA3 (Fig. 2E; corre-
sponding 4DNOESY cross-peaks in Fig. S1). (ii) A salt bridge is
formed between ArgC6 and GluA4 (Fig. 2F). (iii) Favorable
-cation interactions (38) are inferred between TyrA19–ArgC5
and possibly PheB25–ArgC5 (Fig. 2G). The latter is observed in
some but not all members of the ensemble due to impreci-
sion at residue B25. All residues within the insulin moiety
mutated relative to WT (B28, B29, A8 and A14; Fig. S2) are
solvent-exposed. Whereas the A8 and A14 side chain posi-
Figure 2. SCI-b structural ensemble. A, 30 best-fit structures of SCI-b at two views rotated by 180°. B, expanded view of the C domain. C andD, overlay ofWT
porcine insulin (gray; PDB code 4INS) (C) and published SCI-c NMR ensemble (gray; PDB code 2JZQ) relative to SCI-b (red, green, blue) (D). Superpositions were
aligned according to themain-chain atoms of the A1–A8, A13–A19, and B9–B19 segments. A representative model in E–Gwas selected to demonstrate close
proximity of ProC4-H2 and Val
A3-H2 extending the A1–A8 helix (E), the salt bridge between Arg
C6 guanidinium nitrogen and GluA4 carboxylate (F), and
putative -cation interactions between ArgC5 and TyrA19 or PheB25 (G). Color code: A domain (green); B domain (blue); C domain linker (red); disulfide bridges
(yellow sticks); oxygen (red); nitrogen (cyan); carbon (black); and hydrogen (white). Distancemeasurements are indicated by red dashed lines;-cation distances
were measured from centers of the aromatic rings (small black spheres) to the terminal nitrogen atoms of ArgC5.
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tions are well-defined within the ensemble, AspB28 and
ProB29 side chains are imprecise, residing proximal to the
flexible BC junction.
Segmental imprecision in the NMR-derived ensemblemirrors
pattern of order parameters
To probe protein dynamics, 15N relaxation studies were
undertaken to measure residue-specific R1 and R2 relaxation
rates and heteronuclear NOE intensities (Fig. 4A). These data,
probing motions on the picosecond to nanosecond time scale,
enabled calculation of generalized order parameters (S2) (Fig.
4B, top). Such parameters distinguish between rigid (S2 0.65)
and flexible (S2 0.65) elements (39). The latter correlatedwith
sites of fast 1H–2H amide-proton exchange (red squares) as
described below. These residues were fit best by an extended
model-free analysis where S2fast S2 S2slow (see “Experimen-
tal procedures”).
Regions of flexibility or order, as distinguished by the above
1H-15N relaxation studies, correlatedwith patterns of 13CNMR
chemical shifts. Shown in Fig. 4B are secondary-structure prob-
abilities (SSP; bottom) and predicted order parameters (S2;
middle). Ordered regions (S2 and S2  0.65 and SSP	 0) cor-
respond to the three canonical -helices. SSP scores also sug-
gest -strand features within the B23–B30 segment. The latter
segment exhibited increasing flexibility (0.45 S2 0.65) from
B23 to B30 with maximal flexibility within the C domain (resi-
dues 31–36 or C1–C6). Values of S2 and S2 were consistently
0.6 in the C domain. Although relaxation parameters could
not be obtained at ProC4 (which lacks an amide proton), its
chemical shift-derived S2 suggested less disorder than at flank-
ing sites. These dynamic probes may be taken into account to
generate alternative ensembles of protein structures based on
time-averaged MD simulations (30, 31) (see “Discussion”).
SCI-b exhibits enhanced thermodynamic stability
As expected, based on its native-like solution structure,
far-UV circular dichroism (CD) spectra of SCI-b and insulin
lispro implied similar helix contents at 4 °C (Fig. 5, A and B).
Thermal unfolding was monitored by mean residue ellipticity
at 222nm in the range 4–88 °C (Fig. 5C).Whereas insulin lispro
exhibited a marked and irreversible loss of helix content with
increasing temperature, SCI-b displayed only a small and lim-
ited attenuation of ellipticity on heating. On cooling from 88 to
4 °C, the far-UV CD spectrum of SCI-b was indistinguishable
from the original spectrum, although lispro did not refold.
Dynamic light scattering (DLS) revealed that lispro forms large
aggregates following 10 min of incubation at 88 °C, whereas
these conditions do not affect the size distribution of SCI-b
(Fig. S3). Thermodynamic stability was likewise assessed by
CD-monitored guanidine denaturation with application of a
two-state model (Fig. 5D and Table 1). The SCI’s free energy of
unfolding (GCD 4.7(0.1) kcal/mol) was larger than that of
insulin lispro (3.1(0.1) kcal/mol). Respective titration mid-
points (Cmid) were 5.7(0.1) M (SCI-b) and 4.7(0.1) M (insulin
lispro). In such modeling the m-value was higher for SCI-b
(0.82(0.01) kcal/(molM)) than for insulin lispro (0.67(0.01)
kcal/(molM)), suggesting that hydrophobic surfaces are more
effectively desolvated in SCI-b. These estimates depend on the
assumption of two-state unfolding and on fitting of post-tran-
sition baselines (40).
Figure3. Comparisonof SCI structures.A,backbone traces of 18 SCI-bNMR
structures (with the A domain in green; B domain in blue; C domain in red; and
disulfidebridges in yellow)with all sixmonomersof SCI-a (black, crystal refine-
ment from accompanying article (9)); the structures were aligned as in Fig. 2.
Two views are given at relative angle 90° to illustrate differences amongB24–
B30 segments. For clarity, SCI-b structures are at low opacity. B, average pair-
wise backbone r.m.s.d. comparing all monomers of SCI-a to 18 SCI-b struc-
tures. Absent r.m.s.d. values reflect residues with indeterminate electron
densities. C–E, stereo models illustrating side-chain packing of residues B15
and B24 (C), B12 and B26 (D), and A2, A16, and A19 (E) within the mean SCI-b
structure overlaidwith the side-chain electron densities of SCI-amonomer D;
structureswere aligned as in Fig. 2 (SCI-a structure is hidden for clarity). Disul-
fide bridges are shown in yellow, and atoms otherwise colored by domain: A
domain, green; B domain, blue; C domain, red; and atom colors: oxygen, light
red; and nitrogen, light blue.
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To obtain estimates of thermodynamic stability without ref-
erence to two-state modeling, we investigated amide–proton
exchange kinetics in D2O at pD 7.0 and 25 °C. These studies
employed protein samples uniformly enriched in 15N. The first
15N-HSQC spectrum (Fig. 5E; obtained
10min following dis-
solution in D2O) exhibited only four 1H-15N cross-peaks: B15,
B18, A16, and A19. Their progressive 1H-2H exchange in
subsequent HSQCs yielded monoexponential kinetics (Fig.
5F). Comparison of observed (kobs) and intrinsic exchange
rates (kint; calculated using SPHERE (41)) yielded protection
factors (PF  kint/kobs) and in turn provided an estimate of
thermodynamic stability (GpH 7.4): 4.63(0.08) kcal/mol
(averaged over sites B15, B18, and A16; Table 2).6 This esti-
mate, in striking accord with the results of guanidine dena-
turation studies, assumes global-exchange kinetics, i.e. sites
where 1H-2H exchange requires complete unfolding (42, 43).
Subglobal conformational fluctuations are similar to those in
a two-chain analog
Analysis of presumed global 1H-2H exchange at pD 2.4 (Fig.
6A; residues B18, A16, and A19) yielded estimates of GpH 2.8
(Table S2) similar to those at neutral pH. Amide-proton
exchange is markedly slower under these conditions as
intrinsic exchange rates are slower than at neutral pD (41).
Despite such global stabilization, the residue-specific pat-
tern of subglobal and local PFs (Fig. 6B) was in accordance
with a previous analysis of insulin lispro at pD 3.0 (43). Such
similarities provide evidence that the C domain does not
significantly damp subglobal motions on this prolonged time
scale (1 min).
Modeling of receptor-bound SCI-b predicted a novel open
conformation
Models of the complex (Fig. 7) between SCI-b and IR
resulted inCTbeing threaded through the loop formed by the
C domain and B24–B30 segment. The proximity of CT to the
C terminus of the A domain precluded all attempts to form an
un-threaded model. Removing CT residue Phe-714 from the
alignment with the template allowed CT to disengage all con-
tact with SCI-b, resulting in models with CT no longer
threaded through the loop; these models also no longer had
Phe-714 occupying its usual site bounded by IleA2, ValB12,
LeuB15, and IR residues Leu-37 and Phe-64.
Interactions between SCI-b and IR over the 300-ns simula-
tion (Fig. 7A) mirrored those observed in the co-crystal struc-
ture of the WT insulin complex, with notable key conserved
interactions; in particular, PheB24 occupied the spacewithin the
hydrophobic pocket generated by B domain residues ValB12,
LeuB15, TyrB16, and CysB19 and IR residues Asn-15, Leu-37,
Phe-39, and Phe-714. PheB25 projects away from L1–2 and
inserts between CT residues Val-715 and Pro-718 in the same
way as observed in theWTcomplex.Numerous transient intra-
molecular electrostatic interactions were observed: between
TyrB26 and AspB28, between C domain residues GluC1 and
GluC2 with ArgC5 and ArgC6, and between GluA4 and ArgC5.
The C domain of SCI-b contacted the flexible loop on the CR
domain of the IR between residues 264 and 277, predicting
numerous nonspecific interactions. Superposition of bound
SCI-b from this simulation to free SCI-b obtained byNMR (Fig.
7B) illustrates the closed 3 open conformational change on
binding the receptor. Residual -carbon distances from this
6 TyrA19 (residue 55 in SCI-b) exhibited an anomalously large PF, likely to
reflect its proximity to cysteine A20-B19. SPHERE relies on primary struc-
ture and does not take into account disulfide bonding and possible resid-
ual local structure in the unfolded state (41).
Figure 4. Fast time scale dynamical studies. A, 15N spin-lattice (R1, black) and spin-spin (R2, blue) relaxation rates and heteronuclear NOEs (red).
Data were obtained using a 13C,15N-SCI-b sample. Vertical error bars in each plot result from input spectral noise in each T1 or T2 experiment and
subsequent error analysis by the Relax NMR software package (90). B, top, generalized (S2, black squares) and fast (S2fast, red squares) order parameters
calculated from experimental 1H-15N T1, T2, and heteronuclear NOE data with the DYNAMICS software package (91). Predicted generalized order
parameter (S2; middle plot) and secondary structure prediction scores (bottom plot) were calculated by the TALOS software program (60) based on
chemical shifts. In all plots, blue-, red-, and green-shaded areas, respectively, highlight the B9–B19 helix, the C1–C6 segment, A1–A8 helix, and the
A13–A19 helix. For SSP probabilities (bottom), positive values are associated with -helix, whereas negative values suggest -strand; an SSP value of
zero implies disorder.
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overlay (Fig. 7C) and from a superposition of bound structures
to all monomers from the SCI-a crystal structure (Fig. 7D;
structure from Ref. 9) highlight that the B23–C6 segment pri-
marily contributes to the closed 3 open conformational
transition.
SCI-b resembles a premixed soluble-microcrystalline insulin
formulation
The biological activity of SCI-b was tested on SQ injection in
Lewis rats rendered diabetic by streptozotocin (Fig. 8, A and B)
(44). Because its intrinsic PD profile (as defined on i.v. bolus
injection; see our accompanying article (9)) exhibits fast and
delayed phases, our SQ studies were conducted in relation to a
premixed clinical formulation containing soluble and micro-
crystalline components (Humalog Mix 75/25; Lilly) (32). Sol-
uble insulin lispro provided a rapid-acting control (red squares
in Fig. 8). Whereas standard premixed formulations were
developed to provide effective post-prandial bolus (rapid) and
basal (delayed) insulin activity via differential absorption rates
in the SQ depot (black and aquamarine in Fig. 8), a monocom-
ponent solution of SCI-b provided a similar action profile
(green triangles in Fig. 8). The potential implications of this
finding for global health are discussed below.
Discussion
Protein dynamics is integral to a molecular understanding of
structure and function. Segmental flexibility, for example, may
underlie conformational change and in turn facilitate protein–
protein recognition (45). Furthermore, such dynamic features
may accelerate evolution of novel functions (46). In this and our
accompanying article (9), we have sought to apply such bio-
physical principles to the engineering of ultra-stable protein
therapeutics.We first discuss our biophysical findings and then
their translational implications.
SCIs provide an ultra-stable platform for protein engineering
This study focused on an ancestral foldingmotif: the insulin-
related superfamily (7). The high-resolution NMR structure of
an active SCI, designed as an engineered monomer in solution,
provided a foundation for analysis of protein dynamics. Our
findings were extended by use of SA/MD simulations to gain
insight into the dynamics of the parent protein in a crystal lat-
tice and in a model receptor complex.
In the accompanying article in this issue (9), we presented the
design rationale for SCI-a and SCI-b (Fig. 1C). The crystal
structure of SCI-a was determined at moderate resolution (2.8
Å) as a zinc-free hexamer. Because an entire hexamer lies
within the lattice’s asymmetric unit, each protomer was crys-
tallographically independent. Despite the limited resolution of
the diffraction data, the six insulin moieties (i.e. the A- and B
domains) exhibited canonical structures with native dimeriza-
tion. Rootmean square deviation (r.m.s.d.) values among the six
crystallographic protomers were consistent with the struc-
tural variability of WT insulin in different crystalline envi-
Figure 5. Protein folding and thermodynamic stability. A and B, CD spec-
tra of SCI-b (red) and insulin lispro (black) acquired at 25 °C with molar ellip-
ticities calculated and presented as per residue (A) and per molecule (B). C,
forward (43 88 °C) and reverse (883 4 °C) temperature scans of SCI-b (red)
and insulin lispro (black) presented as []222 1 nm, an average of the ellip-
ticities at helix-sensitive wavelengths of 222(1) nm. Distinguishable for-
ward and reverse traces for insulin lispro are labeled.D, comparativeCD-mon-
itored guanidine denaturation studies of SCI-b (red) and lispro (black)
acquiredat 25 °C (solid linesare fits; results given in Table 1). E, 1H-15N-HSQCof
15N-SCI-b 
1500 s after placement of dried protein sample in 100% D2O
potassiumphosphatebuffer. F, exponential decayprofiles generatedbyplot-
tingHSQCcross-peak intensities as a functionof time.Only B15, B18, A16, and
A19 resonances were present in first and subsequent HSQCs due to rapid
baseline base-catalyzed 1H-2H exchange at pH 7.4. Solid lines show single-
exponential fits; parameters are given in Table 2.
Table 1
CD denaturation studies at pH 7.4 and 25 °C
Analog GCDa m-valueb Cmidc
kcal/mol kcal/(molM) M
lispro 3.0 0.1 0.63 0.01 4.7 0.1
SCI-b 4.7 0.1 0.82 0.01 5.7 0.1
a Data are from two-state modeling of CD-monitored denaturation studies (25 °C
and pH 7.4).
b Them-value is the slope of unfolding free energy GU versusmolar concentra-
tion of denaturant and is in units of kcal/(molM).
c Cmid is the guanidine denaturant concentration at which 50% of the protein is
unfolded.
Table 2
NMR-based stability estimates of SCI-b at pH 7.4 (pD 7.0) and 25 °C
Residue kobs kint PF GpH 7.4
s1 106 s1 103 kcal/mol
B15 818 18 1800 2201 49 4.55 0.01
B18 314 7 842 2681 61 4.67 0.01
A16 1040 142 2850 2740 373 4.68 0.08
A19a 850 34 7670 9028 361 5.39 0.02
a The overestimate of GpH 7.4 for A19 is ascribed to its proximity to cystine
A20–B19, which may confound calculation of kint, possibly due to residual
structure in the unfolded state under these conditions.
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ronments (47). Incomplete electron density was observed (to
a varying extent among the six protomers) in the respective
C domains and preceding residues of the B domain (B27–
B30). Precise analysis of side-chain conformations and inter-
actions in the hydrophobic core was limited by the crystal-
lographic resolution.
The crystal structure of SCI-a exhibited a novel overall fea-
ture: in the absence of axial zinc ions, the trimer interfaces were
displaced relative to classical zinc hexamers (9). We speculated
that this novel zinc-free SCI hexamer pertains in -cells to self-
assembly of proinsulin in the endoplasmic reticulum and/or
Golgi apparatus (in which zinc ion concentrations are typically
less than 1 pM (48)). Such native assemblymightmitigate aggre-
gation-coupled misfolding en route to prohormone processing
and storage in glucose-regulated secretory granules. Subse-
quent formation of zinc-insulin hexamers and their microcrys-
tallization within these granules are made possible by a -cell-
specific zinc transporter ZnT8 (49).
Interrelation of stability, dynamics, and function
Interest in SCIs was stimulated by classical studies in which
bifunctional chemical reagents were employed to tether the C
terminus of the B chain to the N terminus of the A chain (50,
51). Such non-standard linkers most often connected the 	-
amino group of LysB29 to the -amino group of GlyA1, thereby
mimicking a connecting peptide. Because D-amino acid substi-
tutions at A1 are well-tolerated (52), an alternative approach
employed a D-LysA1 	-amino group, extending the effective
linker length (51). The relative receptor-binding affinities of the
resulting B29-A1 tethered insulin analogs reflected the number
of atoms within the cross-link: the longer the tether, the stron-
ger the insulin analog–IR binding interaction.
The relationship between linker length and IR affinity sug-
gested that conformational “play” between LysB29 and GlyA1 is
required for high-affinity hormone binding. Biophysical studies
of NA1, N	B29-ethylene glycol-bis-succinoyl-insulin, whose
tether contains 22 connecting atoms inclusive of the B29 side
chain, demonstrated increased thermodynamic stability (Gu
1.9 kcal/mol at 23 °C) and decreased protein flexibility, as indi-
cated by an 
103-fold retardation in overall rate of amide–
proton exchange in D2O (36). To our knowledge, the latter
study provided the first evidence for a biophysical linkage
between inter-chain dynamics and protein stability in the insu-
lin molecule. The present amide 1H-2H exchange studies of
SCI-b similarly revealed increased global thermodynamic
stability through significantly delayed global and subglobal
exchange inD2Oat pD2.4 (pH2.8) relative to analogous studies
of two-chain WT insulin (53).
SCI-b exhibits a combination of structural order and dynamic
disorder
The structure of SCI-b was determined as an engineered
monomer in solution by heteronuclearmultidimensional NMR
methods (10, 11). Whereas SCI-a contained ProB28–GluB29, a
feature of clinical analog insulin glulisine compatible with a
native mode of dimerization (54), paired substitutions AspB28
and ProB29 in SCI-b impaired dimerization; this design com-
bined features of insulinaspart and lispro (12, 13). The 1HNMR
Figure 6. Long time scale dynamics probed by amide-proton exchange kinetics at pD 2.8. A, successive 1H-15N-HSQCs of SCI-b at the stated time points
on dissolution of the protein in 100%D2O at pD 2.4 (pH 2.8). B, plots of PFs against residue number: all observed PFs (top) and an enlarged view of non-global
sites of exchange (bottom). Color code: putative sites of global 1H-2H exchange (red); sites of local exchange (green); sites of subglobal exchange (blue); and
unobserved or absent amide resonances (filled black circles).
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spectrum of SCI-b was found to exhibit sharp resonances even
at a protein concentration of 1mM (9). The pattern of secondary
1H NMR chemical shifts was consistent with stable folding of a
globular domain. Ring-current shifts associated with formation
of classical dimer and trimer interfaces (55) were not observed.
ThemeanNMR structure of SCI-b is similar to but not iden-
tical to crystallographic protomers of SCI-a (Fig. 3A) or WT
insulin (6, 56). Although similarities in core side-chain packing
were observed between the average SCI-b solution structure
and the crystallographic electron density of SCI-a (Fig. 3,C–E),
minor differences occur in segment B24–B28 (backbone
r.m.s.d. in Fig. 3B). The latter is a “naked”-strand in themono-
mer (57) but stabilized as an anti-parallel -sheet at the dimer
interface of the hexamer (6, 56). In accordance with past NMR
studies of two-chain analogs (24, 57, 58), the aromatic side
chains of PheB24 andTyrB26 pack against the-helical core even
in the absence of its partner strand.
Also congruent between solution and crystal structures was
the partial disorder of the C domain. Four types of NMR obser-
vations provide evidence for its reduced structural organiza-
tion. First, the C domain exhibited more limited 1H, 13C, and
15N chemical-shift dispersion than do the A and B domains.
Such attenuated dispersion predicted lower order parameters
relative to those of the insulin moiety (with the exception of
frayedN-terminal residues B1–B3) (59). Second, C domain res-
onances exhibited motional narrowing (57, 58) as evidenced by
greater carbonyl carbon peak intensities (relative to rigid core
residues) in 3D HNCO spectra (Fig. S4). Third, the density of
inter-residue NOEs in the C domain (i.e. contacts either (a)
between residues in the C domain or (b) from the C domain to
the insulin moiety) was lower than the density of NOEs among
the -helical segments; reduced NOE density led to greater
imprecision in a canonical distance-restrained SA ensemble.
Finally, explicit interrogation of main-chain order parameters
Figure7.Model of SCI-bbound toIR.A, stereo viewof bound state of SCI-b (Adomain, yellow; B1–B23,gray) in complexwithIR L1 domain (white) andCT
peptide (green) as obtained fromMD simulations. The open state of SCI-b enables detachment of the B24–B30 segment from the protein core as inWT insulin
with the B24-C6 segmentwrapping around theCT (green) in a thread-likemotif. B,overlays of 20 structures from the 30 structure best-fit SCI-b ensemble (red,
green, blue) and 20 receptor-bound SCI-b structures (gray), as aligned according to the main-chain atoms of the B9–B19, A1–A8, and A13–A19 helices. Black
double arrows highlight open3 closed transition in B24–C6 segment. Disulfides are yellow and labeled by black boxes. N and C termini are as labeled. C,
per-residue average C–C distances (RC-C) between all possible pairwise C comparisons across models in an 18-structure free SCI-b selectively time-
averagedensemble (fromA, right) and18 structures from theboundSCI-b simulation, andD, amongallmodels in an18 structure SCI-amonomer “D” ensemble
(from B, right) and the bound SCI-b ensemble. Error bars in C andD represent standard deviations; error inD is systematically larger than in C due to averaging
over the six independent SCI-a crystallographic protomers. The B9–B19, A1–A8, and A13–A19 helices and C1–C6 segment are shown as shaded boxes.
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(based on 1H-15N T1, T2, and hetNOE measurements at 700
MHz) verified that nanosecond-scale fluctuations are more
marked in the C domain than in the A or B domains. Notably,
regions of structural order (S2 0.65) correlated well with the
three helices, whereas segmental flexibilities in the B1–B4 and
B27–C6 segments were identified by S2 0.65 (Fig. 4).
Dynamical informationmay also be inferred frompatterns of
13C and 1H chemical shifts (60). Comparison of SCI-b and a
reference two-chain analog (two-chain insulin analog contain-
ing AspB10, LysB28, and ProB29-insulin (61)) (Fig. S5) suggested
that the B25–B30 segment is better ordered in SCI-b. Predicted
S2 parameters (where the prime indicates chemical shift-de-
rived values) provides evidence that conformational fluctua-
tions in C-terminal segment of the B domain are damped by the
presence of the C domain, despite the latter’s partial disorder
(Fig. S5, top). Furthermore, the stabilizing ThrA83His substi-
tution in SCI-b was associated with enhanced secondary-struc-
ture propensity (SSP) scores within the A1–A8 helix (Fig. S5,
bottom). These conclusions were strengthened by analysis of
the methyl proton secondary shifts of Ile, Leu, Val, and Ala
residues (probes of aromatic ring currents related to tertiary
structure Table S3) (55).
Complementary evidence for C domain disorder was pro-
vided by qualitative features of the electron-densitymaps of the
variant ProB28–GluB29 SCI-a hexamer (9). In this crystal form
the asymmetric unit was the hexamer itself, and so three inde-
pendent views of the SCI-a dimer were obtained, in turn
providing six views of the C domain. Each dimer exhibited a
canonical B domain interface with discontinuous electron
density between B27 and A1. In most monomers, density in
this region was not interpretable; the most complete (mono-
mer D) included limited density for residues B28–B29 and
C6. Although static disorder in the lattice might in principle
have contributed to such attenuated or discontinuous elec-
tron density, the consistency of these findings and their
coherence with the NMR data strongly suggest that these
incomplete features of the crystal structure represent
dynamic disorder.
Ensemble perspective as a thought experiment
Despite evidence of segmental flexibility, both theNMR (Fig.
2) and X-ray-based (see accompanying article (9)) structural
techniques are limited in their ability to visualize internal pro-
tein dynamics. To provide a depiction of SCI-b that a “Max-
well’s Demon”might observe on the nanoscale, we recalculated
the SCI-b NMR ensemble (Fig. 9A, left) using the Torda-
Scheek-van Gunsteren time-averaged (TA) distance restraint
protocol (30, 31) on either all restraints (Fig. 9A,middle) or in a
modified protocol, wherein time-averaging is applied only to
regions known to be dynamic (Fig. 9A, right). Whereas time
averaging for all restraints increases imprecision globally, selec-
tive time-averaging essentially reproduced the ensemble calcu-
Figure 8. PD profile of SCI-b resembled that of a 75/25 premixed NPH/regular insulin analog formulation. Shown are rat studies of insulin action
followingSQ injectionof stateddose (innanomoles) per 300-g rat of the specifiedSCI or control.A,blood-glucose concentration, andB,percent change relative
to initial blood-glucose concentration. Symbols and doses are defined as inset in (A): data pertaining to SCI-b are shown as green triangles. Two doses of the
premixed formulation (Humalog Mix75/25; Lilly) are provided (black and aquarmarine). A solution of insulin lispro provided a rapid-acting control (red). A
360-min time point for 75/25 at 3.4-nmol dose was not acquired. Samples sizes: (diluent control) n 4; (insulin lispro) n 21; (SCI-b) n 22; (75/25 2.6
nmol) n  7; and (75/25 3.4 nmol) n  6. Error bars represent standard error. C, schematic of a pancreatic -cell and its response to increased plasma
[glucose]. The glucose transporter (brown) regulates glucose entry, whereupon its metabolism generates ATP as an intracellular ligand for the ligand-
gated K channel (blue). Binding of ATP closes K channels and thereby depolarizes the cell membrane, which in turn opens voltage-gated Ca2
channels (green). Entry of Ca2 triggers first-phase exocytosis of secretory vesicles followed by mobilization of storage granules (orange with red
borders). D, plasma insulin concentration curve after subcutaneous injection of stated clinical analogs. The isolated soluble insulin and microcrystalline
are indicated as green and blue curves, respectively. Premixed soluble and microcrystalline insulin is shown in red. D is adapted from http://watcut.
uwaterloo.ca/webnotes/Metabolism/Diabetes.html.
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lated using conventional static distance restraints, thereby
raising confidence in the latter’s physical accuracy. Notably,
segmental flexibility is readily apparent via increased r.m.s.d. in
the B28–C5 segment (Fig. 9, C and D). As a corollary to these
alternative ensembles of the solution structure, an ensemble
model of hexameric SCI-a was generated. First, restraints
derived from the carbon–carbon distances in the SCI-a crystal-
lographic refinement (see accompanying article (9)) were uti-
lized in a conventional SA protocol to generate an ensemble of
60 structures (Fig. 9B, left). Each of these structures was then
subjected to multiconformer simulation wherein the B-factors
of all atoms were fixed (B 2 Å2) either without (Fig. 9B,mid-
dle) or with (Fig. 9B, right) constraining motion of the B5–B27
and A1–A21 segments, which had well-defined electron den-
sity in the original refinement. The protocol for thesemulticon-
former simulations, distinct from standard ensemble X-ray
refinement,7 is described in Fig. S6A. Ensemble-averagedR-fac-
tor calculations (REns, see Equations 2 and 3) yielded REns 
0.37 (“B 2 Å2 crystal simulation”) and REns 0.56 (“B 2 Å2
core constrained”); the former was slightly higher than RFree
0.31 for the single-structure SCI-a refinement (9). Notably, the
REns of themost imprecise ensemble (Fig. 9B,middle) was lower
than that of the core-constrained ensemble (Fig. 9B, right). This
was a consequence ofmore efficient sampling of atompositions
7 Multiconformerapproaches toX-raystructure refinementhavebeendescribed
that probe thermal motion and disorder without over-parametrization
(99–101).
Figure9.Alternative structural ensemblesof SCI-b andSCI-a.A, time-averagedNOE-based ensemble of 98 structures of SCI-b using a standard SAprotocol
(original SA; left). Each structure was run through a TA distance-restrained MD simulation wherein MD time-averaging was activated for all restraints (All
Residues TA; middle). A separate simulation was then performed that enforced time-averaged restraints only for residues residing within flexible regions
(predicted S2 0.65; right). B, each of the 35 hexameric structures generated using carbon–carbon distance restraints derived from the single-structure SCI-a
crystallographic refinement (Hexamer Rebuild SA; left) were subjected tomulticonformer simulation (see Fig. S6A for schematic description of the simulation
procedure) with all thermal B-factors set to 2 Å2 and either no residues constrained (B 2 Å2 crystal simulation; middle) or with the positions of B5–B26 and
A1–A21 constrained (B2Å2with core constrained; right). Themain-chain (C) andheavy-atomside-chain (D) r.m.s.d. per residue for SCI-b (black) or SCI-a (gray)
were calculated from ensembles in A (right) and B (right), respectively. The r.m.s.d. for the SCI-a hexamer ensemble are averaged over all monomers. The
B9–B19, A1–A8, and A13–A19 helices and C1–C6 segment are shown as shaded boxes. Gly residues at positions B8, B20, B23, C3, and A1 were excluded from
heavy-atom side-chain r.m.s.d. calculations.
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relative to the electron density by the ensemble as a whole (Fig.
S6B). Although thiswould in principle also result in a lowerREns
than RFree of the single-structure refinement, the ensemble
models of SCI-a contain C domain residues with no corre-
sponding electron density, resulting in REns  RFree. We
emphasize that over-parametrization in our protocol pre-
cludes use of REns as a comparative refinement parameter; its
value instead corroborates the physical plausibility of the
ensemble.
The above ensemble exhibits a striking overall similarity to
the NMR-derived models in Fig. 9A and provides a nanoscale
perspective of the hexamer as itmight exist in the crystal lattice.
Here, the B1–B3 and B28–C6 segments are flexible (r.m.s.d. in
Fig. 9, C andD), but are constrained to lie within specific chan-
nels defined by neighboring hexamers within the lattice. The
per residue r.m.s.d. (Fig. S7) of other alternative ensembles
(from Fig. 9) highlight the same trends of structural order and
flexibility in the solution and in this ensemble-based visualiza-
tion of the crystal structure.
The ensemble perspectives of SCI-a and SCI-b highlight the
segmental flexibility that foreshadows our MD-based model of
SCI binding to the IR (Fig. 7). We envisage these as models of
what a Maxwell’s Demon, operating on the nanoscale, might
observe. Such a Demon might play an active role in conforma-
tional selection, akin to Maxwell’s mechanism by which envi-
ronmental information is ostensibly extracted to change local
order while still obeying the 2nd law of thermodynamics (62,
63). As the SCI samples conformational space, the Demon
would be charged with selecting an open conformation to
enable receptor binding, a process that likely occurs on the
micro- to millisecond time scale inaccessible to our multicon-
former and TA-NOE simulations. Nevertheless, the above
ensemble perspective provides insight into the process of con-
formational selection by highlighting flexible sites (i.e. B24–
C6) that must undergo closed3 open conformational fluctua-
tion before IR binding. We cannot exclude a mechanism by
which an initial encounter complex by the closed state facili-
tates such opening as envisaged in classical notions of induced
fit; here the Demon would be the receptor itself, coupled to the
regulatory intelligence of the cell.
Model of an SCI–IR complex
In accordance with an extensive prior biochemical literature
(23, 24, 64), recent crystallographic studies of insulin bound to
a domain-minimized insulin micro-receptor (IR, composed
of the L1 and CT domains of IR) demonstrated that the B24–
B27 segment of insulin is displaced from its classical packing
against the A1–A8 and B9–B19 -helices (15, 21). Effected by
changes in Ramachandran dihedral angles flanking PheB24, this
“unhinging” (by 
60° relative to classical crystal structures of
the free hormone dimer or hexamer (6)) enables conserved
non-polar surface (spanned by the side chains of IleA2, ValA3,
PheB24, and PheB25) to engage the receptor (15, 21). An
extended B24–B27 segment lies in a groove between receptor
elements L1 and CT (15, 21). Residues B28–B30, not well-
conserved among vertebrate insulins and dispensable for activ-
ity, were presumed to be disordered in the IR complex.
Accordingly, these three residues would contribute to the C
domain of biologically active SCIs to provide a flexible tether
between ThrB27 and GlyA1. Thus, the present SCI would effec-
tively contain a 9-residue connecting peptide between the
displaced B24–B27 segment and the A1–A8 -helix. Our MD
simulations of such an SCI–IR complex (Fig. 7) have demon-
strated the plausibility of this connection. Themodel is notable
for breakage of C domain interactions with the insulin moiety,
including packing of its central Pro against ValA3; distances
between ValA3 C2 and ProC4 C are 6.1(1.5) Å in the free
NMR ensemble and 16.0(1.9) Å in the predicted SCI–IR
complex. Close packing of these side chains in the predicted
complex is precluded in the IR complex by CT. The bound
SCIconformation thusdiffers fromits free structure (asamono-
mer in solution and as a zinc-free hexamer in a crystal lattice)
with respect to both the position of the B24–B27 -strand and
displacement of the C domain.
Ultimately, segmental flexibilities in SCI-b and SCI-a fore-
shadow the closed to open conformational transition necessary
to bind and activate the IR.MDmodeling of SCI-b andIR (Fig.
7A) illustrates that the C domain, although relatively ordered in
the solution-statemonomer, opens up to wrap around the CT
segment of the IR-A receptor. In these threaded models, the
interactions between insulin A and B domain residues with L1
and CT were native-like, maintaining all interactions
observed in the crystal structure of native insulin in complex
with IR (15, 21). Significant flexibility within the C domain
was observed, with glutamic acids (GluC1 and GluC2) and argi-
nine residues (ArgC5 and ArgC6) forming transient intramolec-
ular electrostatic interactions as well as intermolecular interac-
tions with the N-terminal CT helical residues, ostensibly
stabilizing the bound conformation. Models in which CT did
not thread the C domain resulted in SCI disengagement from
the IR during MD simulations, suggesting an inherent insta-
bility with these models.
The open state of SCI-b thus emulates that of two-chain
insulin through the liberation of the B24–B30 segment from
the protein core. This binding mode justifies SCI-b’s retained
activity in vivo while also rationalizing the biological inactivity
of SCIs with shorter C domain sequences that would sterically
hinder CT-SCI “threading.” The striking difference between
the open and closed states is highlighted by an overlay (Fig. 7B)
of 18 best-fit SCI-b NMR structures (from Fig. 2) with 18 mod-
els of the receptor-bound SCI-b from the MD simulation. The
average per-residue C–C distances across a helix-aligned
ensemble composed of 18 structures each of the bound SCI-b
and free SCI-b quantifies the magnitude of the closed3 open
transition (Fig. 7C), which is localized primarily fromB24 toC6.
A similar trend is seen when comparing the bound SCI-b
ensemble to one monomer of the core-constrained SCI-a mul-
ticonformer simulation ensemble (Fig. 7D). The dynamic prop-
erties of the C domain thus appear to facilitate the conforma-
tional switch from the closed to open (receptor-bound) state
and are thus crucial for SCI function.
The MD simulations of SCI-b in complex with IR recapit-
ulate the flexibility observed experimentally in the SCI mono-
mer and provide evidence of the requirement for these residues
to remain intrinsically dynamic both when unbound and in
complex with the receptor. The requirement for CT to thread
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through the open C domain would be difficult to characterize
experimentally; future attempts to determine the crystal struc-
tures of these SCIs in complex with IR may not resolve the
positions of the dynamicC domain residues. The ability forMD
to probe the time-dependent interactions made by these flexi-
ble domains will be integral for the future design of novel insu-
lin analogs.
Relationship of SCI-b to IGFs
Solution structures of insulin-like growth factors (IGF-I and
IGF-II) have previously been described (65, 66). IGF-I and
IGF-II are homologous to SCI-b but with respective C domain
lengths of 12 and 8 residues. Although similar in overall struc-
ture, there is one striking difference; whereas free SCI-b exhib-
its a well-defined native state, IGFs are well-organized only
as ligand complexes or on specific binding to carrier proteins
(IGF-binding proteins) (67). Indeed, in the absence of a
bound detergent molecule or a bound phage-display peptide
(68), NMR spectra of IGFs exhibit partial aggregation and
conformational broadening on the millisecond time scale
(65, 66). Presumably, ligand-free IGF proteins are in part
molten (66).
As with SCI-b, main-chain dynamic studies of an extended
variant of IGF-I (long-[Arg3]IGF-1) provided evidence of C
domain flexibility with attenuation of corresponding hetNOE
values (65). As a consequence, NMR-based modeling of IGF-I
and IGF-II is remarkable for the imprecision of their respective
C domains (Fig. S8).
Also unlike insulin and proinsulin, free IGF-I undergoes slow
disulfide rearrangement to form an equilibrium between iso-
energetic native and non-native (“swapped”) pairing schemes
(69). By contrast, insulin has a unique ground state (70). Studies
of insulin variants suggest that its native disulfide pairing is
maintained, at least in part, by favorable contacts betweenHisB5
and A chain residues (including CysA6, CysA7, and CysA11);
these long-range interactions have no counterpart in IGFs
wherein HisB5 is substituted by Thr (70, 71).
Translational implications as the fruit of serendipity
In our accompanying article (9), we observed that subtle
sequence variation among SCIs was associated with changes in
their PD profiles as evaluated in rats on i.v. bolus injection.
These findings were serendipitous and not predicted on the
basis of structural modeling. SCI-a, for example, exhibited a PD
profile akin to that of insulin lispro (or WT insulin), whereas
SCI-b exhibited similar initial activity but a subsequent tail of
activity; this tail was even more pronounced in i.v. studies of
SCI-c. Because the plasma half-lives of SCI-a and SCI-c are
similar (each
17 min (72)),8 we presume that these PD differ-
ences arise at the level of the responding target (73). Evidently,
subtle differences in the structure or dynamics of the
hormone–receptor complex can be associated with biological
differences in the duration or time course of attenuation of the
insulin signal.
The biphasic PD profile of SCI-b on i.v. injection (9) moti-
vated the present SQ studies. Biphasic release of insulin by pan-
creatic -cells is a general physiological feature of metabolic
homeostasis (Fig. 8C and Fig. S9A) (74). The two phases of
insulin release correspond to immediate and delayed continu-
ous glucose-responsive exocytosis of insulin-containing secre-
tory vesicles. The latter requires the ATP-dependent mobiliza-
tion of a storage pool of vesicles (orange in Fig. S9A). Such
biphasic secretion, recapitulated in isolated perfused islets
(Fig. S9B) (75), provides a rapid bolus of insulin in response
to a meal followed by prolonged basal release. Whereas both
phases of insulin release are lost in type 1 DM (T1D; due to
autoimmune -cell destruction), early stages of type 2 DM
are characterized by preferential blunting of first-phase
release (76). In the natural history of T2D, eventual -cell
exhaustion also leads to progressive attenuation of second-
phase insulin secretion (76).
The goal of insulin replacement therapy in T1D is to recapit-
ulate the biphasic physiological pattern of post-prandial pan-
creatic insulin secretion and thereby prevent either hyperglyce-
mic or hypoglycemic excursions. This goal has stimulated the
development of rapid and basal insulin analogs (77) and sophis-
ticated insulin delivery devices, including an “artificial pan-
creas” in which the output of a continuous glucose monitor
controls (via a predictive algorithm) a pump as a closed-loop
system (77). Rigorous glycemic control in T1D has been
shown to delay or prevent microvascular complications and
may also reduce the risk of macrovascular disease (78). The
associated technologies primarily pertain to patients in
affluent societies.
To an increasing degree over the next two decades, the
majority of new cases of T2D are predicted to be in the devel-
oping world (5). This reflects an intersection between genetic
factors and cultural changes, including urbanization, Western
diet, and level of physical exertion (5). For unknown reasons,
the incidence of T1D (classically a syndrome of northern lati-
tudes and somore prevalent amongCaucasians) is also increas-
ing toward the equator (5). The predominant form of insulin
prescribed in such populations is a premixed formulation for
twice-a-day injection. Such products contain (a) a short-acting
soluble component (as zinc insulin analog hexamers) and (b) a
long-acting microcrystalline insulin suspension; the latter con-
sists of zinc-stabilized protamine–insulin analog complexes
(neutral protamine Hagedorn; NPH (77)). An example is pro-
vided by HumalogMix75/25 (Lilly), in which 75% of the hor-
mone (insulin lispro) is contained within the NPH microcrys-
tals and 25% is in the soluble phase (32); a similar product in
broad clinical use contains an insulin aspart mixture of 70%
NPH and 30% soluble analog (Novolog Mix 70/30 from
Novo-Nordisk).
The essential idea underlying design of premixed formula-
tions exploits the combined PK properties of the soluble and
microcrystalline insulin components within the SQ depot (Fig.
8D). The PD properties of the insulin analog are identical once
in the bloodstream. Biphasic absorption of the rapid and
delayed components following breakfast and dinner provides
reasonable glycemic control in patients for whom these are the
major meals (i.e. lunches are small). Disadvantages derive from
8 Whereas commercial insulin RIA/ELISA kits enabled detection of SCI-a and
SCI-c (following establishment of a standard curve), the available antisera
did not efficiently recognize SCI-b (72).
Heat-stable insulin dynamics
J. Biol. Chem. (2018) 293(1) 69–88 81
the cost and complexity of manufacture and from the suscepti-
bility of insulin component in NPH microcrystals to thermal
degradation.
We have observed that the biphasic PD properties of SCI-b
fortuitously recapitulated the biphasic PK-based profile of stan-
dard premixed formulation but in a solution that contains a
single phase. The striking resistance of SCI-b to thermal degra-
dation (predicting an extended shelf life) could be of clinical
advantage in regions of the developing world lacking access to
refrigeration (2, 5).
Concluding remarks
This study has described the high-resolution solution struc-
ture and dynamics of an activemonomeric SCI. Ensembles gen-
erated by alternative SA protocols andmulticonformer simula-
tions extended our findings, providing alternative depictions of
protein dynamics. Segmental flexibility in the foreshortened C
domain of the SCI foreshadows a closed3 open transition on
binding to the IR: an SCI-CT threading model was supported
byMD simulation.Whereas this model rationalizes a wealth of
prior biochemical data pertaining to smaller, inactive SCIs,
optimization of this structural switch in a therapeutic formula-
tion promises to extend the unrefrigerated shelf-life of insulin
pharmaceuticals and enhance their global access in the face of
an emerging DM pandemic (5).
It would be of future interest to test our MD-based model
of an SCI–IR complex through crystallographic studies. If
observed in such model complexes and relevant to holorecep-
tor binding, the proposed threading mechanism predicts an
abrupt transition between inactive SCIs (whoseCdomains con-
tain three or fewer residues) and active SCIs (four or more res-
idues). A systematic series of SCIs might therefore provide a
molecular ruler by which to probe the coupling between con-
formational change and SCI–CT threading. The same SCI
series might exhibit an analogous yet uncorrelated transition
from fibrillation resistance to susceptibility. Because cross-
assembly entails a more marked conformational change than is
predicted on receptor binding, we imagine that longer C
domains would be needed in a fibril to span the gap between
B30 and A1. Comparison between these independent rulers
thus promises to define the sweet spot for ultra-stable insulin
analog design.
Experimental procedures
Construction of SCI precursor expression vectors
A set of synthetic plasmids (pPICZ) was designed and con-
structed for expression in yeast P. pastoris to enable direct
secretion of SCI precursors (SCI-a, SCI-b, and SCI-c; Fig. 1C)
into the media (79, 80). These plasmids were constructed as
described in the accompanying article (9).
Biosynthesis of SCI precursor
SCI precursor biosynthesis followed a method adapted for
insulin production in P. pastoris yeast (80) as described in the
accompanying article (9). This study also adapted a protocol
(81) for isotopic labeling of the proteins. Cells from the most
expression-optimized colonywere inoculated in 10ml of sterile
YPG  Zx1 (1% yeast extract, 2% peptone, 2% glycerol, 100
g/ml Zeocin) in a 50-ml Falcon tube and grown overnight at
30 °C and a stirring speed 225 rpm (C25KC Incubator/Shaker;
New Brunswick Scientific, Edison, NJ). The 10-ml culture was
then added to 100 ml of YPG  Zx1 in a sterile 500-ml Erlen-
meyer flask and grown another 24 h at 30 °C and 225 rpm. Cells
were then pelleted and resuspended into 1 liter of sterile YPS
(1% yeast extract, 2% peptone, 0.1 M sorbitol) in 2-liter flasks
and incubated 24 h at 30 °C and 225 rpm. Cells centrifuged in
sterile 400-ml bottles were then resuspended inmedia contain-
ing 0.17% yeast nitrogen base without amino acids with 0.5%
[15N](NH4)2SO4 and 1% [13C]methanol (both from Cambridge
Isotopes, Tewksbury, MA). For 15N-only labeling, unlabeled
methanol was used for induction. For non-isotopically labeled
protein, both unlabeled (NH4)2SO4 and methanol were used.
Cells were incubated at 20 °C and 225 rpm for 48 h with addi-
tion of methanol to 0.5% after the first 24 h. Cells were pelleted
in 400-ml centrifuge bottles (4500  g for 20 min), and the
supernatant was filtered through 0.22-m Stericup filters
(Merck Millipore, Billerica, MA).
Purification of yeast product
For purification of 13C,15N-SCI-b precursor, hydrophobic
interaction chromatography (butyl-Sepharose 4 Fast Flow res-
in; GE Healthcare) was first used to capture protein from the
filtered supernatant. All reverse-phase HPLC (rp-HPLC) puri-
fications were performed using aqueous 0.1% trifluoroacetic
acid (TFA) as Buffer A and 0.1% TFA in acetonitrile as the
organic modifier (Buffer B). Preparative purifications utilized a
Waters 2545 quaternary pumping system with FlexInject
(Waters). The precursor was isolated by preparative C4
rp-HPLC (C4 Proto 300 Å, 10-m, 250 20mm;Higgins Ana-
lytical Inc., Mountain View, CA). For purification of all other
precursors (unlabeled and 15N-only labeled), a minimized rp-
HPLC-only protocol was used. To the filtered cell media, ace-
tonitrile and TFA were added to 20 and 0.1%, respectively, fol-
lowed by preparative C4 rp-HPLC (as above). In either case,
eluted SCI was collected and lyophilized.
Enzymatic cleavage and SCI purification
TheAchromobacter protease I (ACP-1) gene fromAchromo-
bacter lyticus (82)was expressed inEscherichia coli and purified
as described in the accompanying article (9). Enzymatic con-
version of SCI precursor to SCI (via cleavage of the EEAEAEA-
EPK spacer peptide at the C terminus of lysine) was also per-
formed as described (9). Converted 13C,15N-SCI-b was first
purified by preparative C8 rp-HPLC (C8 Kromasil 100 Å,
10-m, 250 20 mm; Akzo Nobel, Amsterdam, Netherlands).
Final purification utilized a C18 column (C18 Proto 300 Å,
10-m, 250 20 mm; Higgins Analytical Inc.). SCI purity was
verified to be 98% using analytical C18 rp-HPLC (C18 Dis-
covery BIOwide 300 Å, 5-m, 250  4.6 mm; Supelco, Belle-
fonte, PA). For unlabeled and 15N-SCI-b, the digestion reaction
was purified by preparative C4 rp-HPLC (as above). Eluted SCI
was lyophilized and the purity assessed to be98% by C4 ana-
lytical rp-HPLC.
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Optical spectroscopy
Far ultraviolet (255–200 nm) CD spectra were obtained at
high signal-to-noise for insulin analogs using a CD spectropo-
larimeter (Aviv Biomedical Inc., Lakewood, NJ) equipped with
temperature control and an automated titration unit. CD spec-
tra (255–200 nm) of buffer were first obtained using degassed
potassium/phosphate buffer (10 mM KH2PO4/K2HPO4 (pH
7.4) buffer with 50 mM KCl) at 4, 25, and 37 °C using a 30-s
averaging time. As these spectra did not vary with temperature,
the 25 °C KPi dataset was subtracted from all protein spectra.
Samples were prepared at a concentration of 20–70Mprotein
in KPi buffer, brought to pH 7.4 with KOH, and placed in a
parafilm-sealed 1-mm path-length quartz cuvette. Full CD
spectra (255–200 nm)were acquired at 4, 25, and 37 °Cwith 0.5
nm wavelength resolution and a 15-s photocount averaging
time.All CD sampleswere quantitated via reference-subtracted
UV-visible spectra acquired in KPi buffer with a UV-visible
spectrometer (Aviv Biomedical Inc.) and a 3-mm quartz
cuvette. Protein concentrations in potassium/phosphate
buffer were calculated using absorbance at 
  280 nm and
estimated extinction coefficients predicted by the on-line
ExPASy ProtParam tool.
CD studies of protein unfolding
To assess temperature dependence and reversibility of pro-
tein folding, a thermal scan (monitored at helix sensitive wave-
lengths 222(1) nm) was performed on all CD protein samples
(see above) from 4 to 88 °C followed by a reverse gradient from
88 to 4 °C (all in 4 °C steps). A full CD spectrum (255–200 nm)
was then acquired at 4 °C to verify reversible folding (or lack
thereof). Thermodynamic stabilities in KPi buffer at 25 °C were
determined by monitoring guanidine-induced unfolding at the
helix-sensitive wavelength 222 nm as described (83).
Heat-induced aggregation probed by DLS
Aqueous aliquots of insulin lispro or SCI-b necessary to
obtain 0.6 mM protein solutions in 30-l final volumes were
pipetted into separate Eppendorf tubes and lyophilized. The
powder was then dissolved in “Tris diluent” (25 mM Tris-HCl
(pH 7.4) containing 16 mg/ml glycerin, 1.6 mg/mlmeta-cresol,
0.65 mg/ml phenol, and ZnCl2 at a ratio of three Zn2 ions per
insulin hexamer). All buffer components (i.e. deionized water,
4Tris-HCl diluent (pH 7.4), and 10mMZnCl2) were degassed
via nitrogen bubbling for 15 min and then syringe-filtered
(0.02-m Whatman Anton 10 filters; Sigma), followed by
centrifugation (5 min at 16,100  g). Gentle mixing of the fil-
tered components with lyophilized protein was performed by
repeated pipetting.
Unheated samples were probed by DLS as described (9) fol-
lowing 30min of incubation at room temperature. Heated sam-
ples were placed on a heat block set to 88 °C for 10 min to
replicate the high temperatures encountered during the CD-
monitored thermal scan (see above) before DLS measurement.
NMR spectroscopy
All spectra were acquired at a protein concentration of 0.6
mM at 25 °C with a Bruker AVANCE 700 MHz spectrometer
equipped with a triple-resonance cryoprobe (Bruker Biospin
Corp, Billerica, MA) as described (83). All chemical shifts were
calibrated in parts/million (ppm) relative to 4,4-dimethyl-4-
silapentane-1-sulfonic acid as an internal standard. All raw
NMR spectra (except four-dimensional data) were processed
using Bruker’s TopSpin software before analysis using third
party software packages, as described below.
NMR structure determination
A 4D time-shared 13C,13C/13C,15N/15N,15N NOESY was
acquired as described (11), followed by a suite of 2D and triple-
resonance 3D spectra, including 15N HSQC, 13C HSQC,
aromatic 13C HSQC, HNCA, CBCA(CO)NH, HN(CO)CA,
H(CCCO)NH, (H)CC(CO)NH, HNCACB, HCC-TOCSY, and
13C NOESY-HSQC (10). Because of a large total acquisition
time, 15N HSQC spectra were acquired periodically to verify
sample consistency. After processing 2D and 3D spectra in
TopSpin, resonance assignment was performed using Sparky
(84). The 4D time-shared NOESY dataset was processed using
NMRPipe (85) into three separate 4D spectra consisting of a 4D
13C,13C NOESY, 4D 13C,15N NOESY, and 4D 15N,15N NOESY,
which were subsequently imported into Sparky for assignment.
Custom routines written in R-script and Bash unix shell per-
formed automated NOE distance restraint generation and
structural refinement according to established protocols (28).
Distance restraints were obtained from 4D NOESY data; dihe-
dral-angle restraints for all non-dynamic residues were pre-
dicted by TALOS (60, 86) using chemical shifts. An SA pro-
tocol (28) performed by XPLOR-NIH (87) generated 98
structures; refinement involved iterative identification of best-
fit structures followed by relaxation of distance restraints (or
removal, if restraint became6 Å) and ensemble recalculation
until no restraint violations 0.4 Å were found. The final
ensemble (generated using 1370 NOE and 75 dihedral angle
restraints) was consistent with observed 4D NOESY data. All
structural figures were generated in PyMOL (Schro¨dinger,
LLC, New York).
1H-2H amide–proton exchange
To avoid potential artifacts in the SCI-b CD-monitored gua-
nidine titration, 1H-2H amide exchangewas performed in 100%
D2O (Cambridge Isotopes) containing 10 mM KH2PO4/
K2HPO4 (pH 7.4) and 50 mM KCl (100% D2O-KPi) to replicate
the salt conditions of the guanidine titration studies. KPi buffer
was first added to lyophilized 15N-SCI-b (to 0.6 mM protein),
adjusted to pH 7.4 with KOH, and the sample lyophilized. Fol-
lowing this, the NMR spectrometer was shimmed, the 1H/15N/
13C probe channels tuned, and the 90° 1H pulse calibrated using
a separate SCI-b sample in 100% D2O-KPi. A 90° 1H pulse of
15.94 s (1 dB power level) was used. The lyophilized 15N-
SCI-b sample (containing KPi salts at pH 7.4) was placed on ice
followed by addition of chilled 100% D2O with gentle mixing
and placement in a Shigemi tube. The sample was shimmed at
25 °C and
30 successive 2D 15N-HSQC spectra were acquired
and processed in batch.
For pH 2.8 amide exchange studies, lyophilized protein was
directly mixed with 100% D2O, followed by pH measurement
(using an electrode rinsed with 100%D2O) verifying the sample
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at pD2.43 (pH2.83). This samplewas used for spectrometer 90°
pulse and probe calibration. A multirun was set up to acquire
2D 15N-HSQC spectra once every 3 h for about 1 week at 25 °C.
Resonance assignments needed to extract kobs from pH 2.8
amide exchange were obtained from a separate analog identical
to 13C,15N-SCI-b but with AlaC4 instead of ProC4. Despite this
mutation, the pH 3 and pH 7.4 15N-HSQCs of the two analogs
are essentially identical.
The observed rate of amide exchange, kobs, for each resonance
wasdeterminedusing theSparky “rh” extension.The intrinsic rate
of exchange for each residue, kint, was calculated using the SCI-b
sequence, pH 2.8 or 7.4, and 100% D2O content as input parame-
ters in the on-line SPHERE program (41). Calculating kobs/kint
gives the PF, which can be inserted into Equation 1,
GAmEx RT lnPF (Eq. 1)
to obtain a model-free estimate of thermodynamic stability,
GAmEx. Here, R is the ideal gas law constant, and T is the
absolute temperature. GAmEx values obtained from pH 2.8
amide exchange studies are defined as GpH 2.8, whereas
GpH 7.4 indicates an amide exchange result obtained at pH 7.4.
The 1H-15N cross-peak of LeuB15 was omitted from pH 2.8
analysis due to overlap with that of IleA10 (Fig. 6A). Very slow
exchange at pH 2.8 led to significant error in GpH 2.8 from
these resonances.
1H-15N NMR relaxation studies
2D spin-lattice (T1), spin-spin (T2), and hetNOE 15N-HSQC
spectra were acquired at 700 MHz as described (88, 89). Het-
NOE spectra, which probe sub-nanosecond motions, used a
relaxation delay of 6 s. T1 and T2 relaxation experiments yield
information about internal protein dynamics; these experi-
ments used a relaxation delay of 2 s. Spectra were processed in
TopSpin and assigned in Sparky. Relaxation rates (R1 and R2)
and NOE values were calculated by Relax NMR (90); errors in
these values were derived from spectral noise. DYNAMICS
generated by-residue generalized order parameters, S2, as
described (91), using a rotational correlation time of 4.8 ns (iso-
tropic diffusion model) and fixed chemical shift anisotropy of
240 ppm. This analysis detected sites of fast chemical
exchange by fitting data for some residues to an extendedmod-
el-freemodel that also presents the fast dynamics order param-
eter S2fast S2 S2slow.
TALOS was used to predict both secondary structure pro-
pensity (SSP) scores and generalized order parameters (S2,
which do not account for chemical exchange) from chemical
shifts as described (60).
Alternative ensemblemodels of SCI-a and SCI-b
Using XPLOR-NIH, the refined 98 structure ensemble of
SCI-b generated by distance-restrained SA was subjected to
Verlet equilibration at 300 K for 10 ps, followed by another 25-ps
simulation where NOE distance restraints were applied using the
Torda-Sheek-van Gunsteren TA NOE protocol (30, 31) and a
decayconstantof0.625ps.Timeaveragingwasapplied toeither all
residues or, in a separate simulation, to only those with predicted
order parameter lower than 0.65 (i.e. dynamic regions).
Because of incomplete electron density in the original SCI-a
crystal refinement (see accompanying article in this issue (9)), a
model of the “complete” structure of the hexamer was artifi-
cially generated. First, a custom MATLAB script calculated all
possible carbon–carbon distances in the SCI-a structure and
generated a restraint for any distancewithin the range 35–40Å.
These 
200 restraints were used in the XPLOR-NIH SA pro-
tocoltobringastartingstructureofsixindependentSCI-amono-
mers (generated in PyMOL using an SCI-b structure as a tem-
plate) together, resulting in a coarse hexameric structure. To
this structure, restraints derived from all carbon–carbon dis-
tances within 1.8–30Å (
670,000 restraints) in the SCI-a crys-
tal refinementwere applied to generate an ensemble of 60 hexa-
meric structures (labeled Hexamer Rebuild SA in Fig. 9B). A
multiconformer simulation (all B-factors fixed to B  2 Å2)
utilizing reflection data from SCI-a was performed on each
individual structure fromHexamer Rebuild SA.Here,B-factors
of 2 Å2 were chosen so that the mean square displacement (u,
obtained from the equation B 82u2) of carbon atoms would
be just under 0.17 Å or
10% the van der Waals radius of car-
bon (1.7A). A separate simulation was performed wherein any
residue that was well-resolved in the SCI-a crystal refinement
was spatially fixed, whereas all others retained B-factors of B
2Å2, allowing only dynamic regions tomove, paralleling theTA
NOE ensembles generated for SCI-b. The protocol for ourmul-
ticonformer simulation, modifications of slow cooling crystal-
lographic SA (20003 300 K; 25 K reduction per 5-fs time step),
is given in schematic form in Fig. S6. R-factors for each struc-
ture in the multiconformer ensemble, Ri, were calculated using
the standard Equation 2,
Ri 
hPFObs(h) kFCalc(h)Ph FObs(h) (Eq. 2)
where FObs are observed structure factors, a function of Miller
indices h . Fcalc and k are calculated structure factors and the
weighting coefficient as obtained during the B  2 Å2 simula-
tions. From here, the ensemble averaged R-factor, REns, is cal-
culated using Equation 3,
REns  iRi/N (Eq. 3)
where n 60, the number of structures in the ensemble. Note
that for clarity only 35 structures of each hexameric ensemble
are shown in Fig. 9.
Homologymodeling of SCI-b bound to insulinmicro-receptor
Models of SCI-b in complex with the IR isoform A (IR)
L1-CR (IR), including the IR CT domain, were generated
using the MODELLER (92) program utilizing the crystal struc-
ture of native insulin in complex with the micro-receptor and
CT as a template. To account for glycosylation a single
N-linked N-acetyl-D-glucosamine carbohydrate at each of the
IR residues Asn-16, Asn-25, Asn-111, Asn-215, and Asn-255
was included. From 25models created, themodel with the low-
estMODELLER objective functionwas used in subsequentMD
simulations.
MD simulations were performed using the GROMACS (ver-
sion 5.1.2) (93) suite of programs and the CHARMM36 (94, 95)
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force field. Briefly, the simulation consisted of an initial steepest
decent minimization, a short 50-ps positionally restrained MD
holding the protein fixed, and finally unrestrained MD for 300
ns. The system was solvated using the TIP3P water model in a
cubic box extending 10Åbeyond all atoms andutilized periodic
boundary conditions. The systemwasmade electrically neutral
to a final ionic strength of 0.1 Mwith the addition of sodium and
chloride ions; ionizable residues were assumed to be in their
charged state at a pH of 7. The temperature of the system was
maintained by coupling the protein and solvent independently
to a velocity rescaling (96) thermostat at 300 K with a time
constant of 0.1 ps. Pressure was controlled to 1 bar using a
Berendsen barostat (97) with a coupling of 0.5 ps. A cutoff of 12
Å was used to account for non-bonded interactions and the
particle-mesh Ewald method (98) to account for long-range
electrostatics applying a grid width of 1.2 Å and a sixth-order
spline interpolation. Neighbor searching applied a Verlet grid
cutoff schemewith a neighbor-list update frequency of 40 steps
and a time step of 2 fs. All bond lengths were constrained with
the P-LINCS algorithm. Coordinates of the model were ar-
chived every 15 ns after an initial 45 ns equilibration.
Biological testing in diabetic rats
HumalogMix75/25 (Lilly) provided a biphasic standard on
SQ injection. Insulin lispro or SCI-b was dissolved at concen-
trations for which each 100-l volume contained the doses (in
nanomoles) specified in Fig. 8. These proteins were dissolved in
Lilly diluent (a product containing 3.8 mg/ml sodium phos-
phate (pH 7.4), 16 mg/ml glycerin, 1.6 mg/mlmeta-cresol, 0.65
mg/ml phenol). The formulations each contained ZnCl2 at a
ratio of three Zn2/1 insulin hexamer. Insulin purity was veri-
fied by C4 analytical rp-HPLC as above. Protein-free Lilly dil-
uent was used as a negative control (buffer only). Male Lewis
rats (mean bodymass
300 g) were rendered diabetic by strep-
tozotocin (44) and studied as described in our accompanying
article (9). Because of day-to-day variation (between rats and in
the same rat on different days), 4–8 rats were injected per ana-
log formulation on each test day, and the experiments were
repeated on one or more non-consecutive days to obtain a
larger sample size.
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